Opinion|Videos|November 4, 2024

Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

Panelists discuss how complement inhibitors work to treat generalized myasthenia gravis (gMG), evaluating their efficacy and safety profiles based on FDA approvals and clinical experience.

Video content above is prompted by the following:
  • Complement inhibitor agents have been approved by the FDA for treatment of gMG. Provide an overview of their mechanism of action and your overall impressions of the efficacy and safety of these agents.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME